---
layout: default
title: Felodipine
description: "Felodipine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 7 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 70
evidence_level: L4
indication_count: 7
---

# Felodipine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>7</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Felodipine è—¥å¸«è©•ä¼°ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Felodipine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Felodipine æ˜¯éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å¯ç”¨æ–¼å¤šç¨®è‚ºé«˜å£“å’Œæƒ¡æ€§é«˜è¡€å£“ï¼Œé€™äº›é æ¸¬å…·æœ‰è—¥ç†å­¸åŸºç¤ä½†ç¼ºä¹å°ˆé–€çš„è‡¨åºŠè©¦é©—è­‰æ“šã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Felodipine (éæ´›åœ°å¹³) |
| DrugBank ID | DB01023 |
| å°ç£å•†å“å | éæ´›åœ°å¹³ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | é«˜è¡€å£“ã€å¿ƒçµç—› |
| é æ¸¬æ–°é©æ‡‰ç—‡ | pulmonary hypertension owing to lung disease and/or hypoxiaã€pulmonary hypertension with unclear multifactorial mechanismã€malignant renovascular hypertensionã€malignant hypertensive renal diseaseã€hypertensive disorderã€Braddock syndromeã€chronic pulmonary heart disease |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.9991 (pulmonary hypertension) |
| è­‰æ“šç­‰ç´š | L4 (å‰è‡¨åºŠ) è‡³ L5 (åƒ…é æ¸¬) |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. pulmonary hypertension owing to lung disease and/or hypoxia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.91%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Felodipine ä½œç‚ºäºŒæ°«å¡å•¶é¡éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘ï¼Œå…¶å°é æ¸¬é©æ‡‰ç—‡çš„æ½›åœ¨ç™‚æ•ˆæœ‰ä»¥ä¸‹è—¥ç†å­¸åŸºç¤ï¼š</p>

<ol>
<li><strong>è¡€ç®¡æ“´å¼µä½œç”¨</strong>ï¼šé˜»æ–· L-type éˆ£é›¢å­é€šé“ï¼Œå°è‡´å‹•è„ˆå¹³æ»‘è‚Œé¬†å¼›</li>
<li><strong>è‚ºè¡€ç®¡æ“´å¼µ</strong>ï¼šç†è«–ä¸Šå¯é™ä½è‚ºè¡€ç®¡é˜»åŠ›</li>
<li><strong>è…è¡€ç®¡æ•ˆæ‡‰</strong>ï¼šå¯æ”¹å–„è…è‡ŸçŒæµï¼Œå°æƒ¡æ€§é«˜è¡€å£“æ€§è…ç—…å¯èƒ½æœ‰ä¿è­·ä½œç”¨</li>
<li><strong>åŒé¡è—¥ç‰©ç¶“é©—</strong>ï¼šå…¶ä»–éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘(å¦‚ nifedipine)å·²è¢«ç”¨æ–¼æŸäº›é¡å‹çš„è‚ºé«˜å£“</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33862277/" target="_blank">33862277</a></td><td>2021</td><td>Article</td><td>Ageing research reviews</td><td>Hypoxia and brain aging: Neurodegeneration or neuroprotection?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37328448/" target="_blank">37328448</a></td><td>2023</td><td>Article</td><td>Advanced science (Weinheim, Ba</td><td>N4-Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39841808/" target="_blank">39841808</a></td><td>2025</td><td>Article</td><td>Science translational medicine</td><td>Hypoxia as a medicine.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28972206/" target="_blank">28972206</a></td><td>2017</td><td>Article</td><td>Nature reviews. Immunology</td><td>Regulation of immunity and inflammation by hypoxia in immunological niches.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34618295/" target="_blank">34618295</a></td><td>2022</td><td>Article</td><td>Metabolic brain disease</td><td>Cognitive impairment caused by hypoxia: from clinical evidences to molecular mec...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31706510/" target="_blank">31706510</a></td><td>2019</td><td>Article</td><td>Trends in cancer</td><td>DUBs, Hypoxia, and Cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21328446/" target="_blank">21328446</a></td><td>2011</td><td>Article</td><td>Journal of cellular biochemist</td><td>Hypoxia-mediated biological control.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40347693/" target="_blank">40347693</a></td><td>2025</td><td>Article</td><td>Redox biology</td><td>Hypoxia in multiple sclerosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34535359/" target="_blank">34535359</a></td><td>2021</td><td>Article</td><td>Clinical oncology (Royal Colle</td><td>Therapeutic Modification of Hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11172576/" target="_blank">11172576</a></td><td>2000</td><td>Article</td><td>Respiratory care clinics of No</td><td>Mechanisms of hypoxemia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24557798/" target="_blank">24557798</a></td><td>2014</td><td>Article</td><td>Journal of applied physiology </td><td>Translation in progress: hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4585366/" target="_blank">4585366</a></td><td>1973</td><td>Article</td><td>Revista medica de Chile</td><td>[Cerebral hypoxia].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36100192/" target="_blank">36100192</a></td><td>2022</td><td>Article</td><td>Journal of controlled release </td><td>Research progress on tumor hypoxia-associative nanomedicine.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2164797/" target="_blank">2164797</a></td><td>1990</td><td>Article</td><td>Annales francaises d&#x27;anesthesi</td><td>[Postanoxia encephalopathies].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37915135/" target="_blank">37915135</a></td><td>2023</td><td>Article</td><td>BMB reports</td><td>Regulation of CMGC kinases by hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30423905/" target="_blank">30423905</a></td><td>2018</td><td>Article</td><td>International journal of molec</td><td>Hypoxic Microenvironment and Metastatic Bone Disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8817697/" target="_blank">8817697</a></td><td>1996</td><td>Article</td><td>Progress in neurobiology</td><td>Hypoxia and brain development.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18345017/" target="_blank">18345017</a></td><td>2008</td><td>Article</td><td>Cell death and differentiation</td><td>Hypoxia-inducible factor: roles in development, physiology, and disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27146279/" target="_blank">27146279</a></td><td>2017</td><td>Article</td><td>Cephalalgia : an international</td><td>Hypoxic mechanisms in primary headaches.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28493839/" target="_blank">28493839</a></td><td>2017</td><td>Article</td><td>Oncotarget</td><td>Hypoxia inducible factors in hepatocellular carcinoma.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. pulmonary hypertension with unclear multifactorial mechanism</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. malignant renovascular hypertension</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td>N/A</td><td>N/A</td><td>Article</td><td>N/A</td><td></td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. malignant hypertensive renal disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Braddock syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. chronic pulmonary heart disease</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2487551/" target="_blank">2487551</a></td><td>1989</td><td>Article</td><td>Cardiovascular drugs and thera</td><td>Felodipine in severe chronic congestive heart failure: acute effects on central ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2838319/" target="_blank">2838319</a></td><td>1988</td><td>Article</td><td>The European respiratory journ</td><td>Cardiac function and central haemodynamics in severe chronic obstructive lung di...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3154329/" target="_blank">3154329</a></td><td>1988</td><td>Article</td><td>Cardiovascular drugs and thera</td><td>Calcium channel antagonists. Part III: Use and comparative efficacy in hypertens...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. Prinzmetal angina</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.07%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ9 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1746458/" target="_blank">1746458</a></td><td>1991</td><td>Article</td><td>The American journal of cardio</td><td>Felodipine (once daily) versus nifedipine (four times daily) for Prinzmetal&#x27;s an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8013514/" target="_blank">8013514</a></td><td>1994</td><td>Article</td><td>European heart journal</td><td>Once daily felodipine in preventing ergonovine-induced myocardial ischaemia in P...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7744087/" target="_blank">7744087</a></td><td>1995</td><td>Article</td><td>European heart journal</td><td>24 h anti-anginal and anti-ischaemic effects with once daily felodipine. A doubl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7728649/" target="_blank">7728649</a></td><td>1995</td><td>Article</td><td>The Canadian journal of cardio</td><td>The evolving role of calcium channel blockers in the treatment of angina pectori...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14689111/" target="_blank">14689111</a></td><td>2003</td><td>Article</td><td>Herz</td><td>[Differential therapy with calcium antagonists].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3345765/" target="_blank">3345765</a></td><td>1988</td><td>Article</td><td>European heart journal</td><td>Exercise-induced intermittent angina and ST-segment elevation in Prinzmetal&#x27;s an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19052677/" target="_blank">19052677</a></td><td>2008</td><td>Article</td><td>The Canadian journal of cardio</td><td>Vasospasm-induced polymorphic ventricular tachycardia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2909138/" target="_blank">2909138</a></td><td>1989</td><td>Article</td><td>The American journal of cardio</td><td>Effect of felodipine on hyperventilation-induced ischemic attacks in variant ang...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15222138/" target="_blank">15222138</a></td><td>2004</td><td>Article</td><td>Orvosi hetilap</td><td>[Nicergoline-induced Prinzmetal angina. &quot;Heartache&quot; instead of headache].</td></tr>
</tbody>
</table>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| ä¸»è¦è£½åŠ‘ | éæ´›åœ°å¹³ç·©é‡‹éŒ  |
| å¸¸è¦‹åŠ‘é‡ | 5mg, 10mg |
| æ ¸å‡†é©æ‡‰ç—‡ | é«˜è¡€å£“ã€å¿ƒçµç—› |

### ç›¸é—œè¤‡æ–¹è£½åŠ‘
- å« Felodipine + Enalapril çš„è¤‡æ–¹è£½åŠ‘ç”¨æ–¼é«˜è¡€å£“æ²»ç™‚
- ä¸å»ºè­°ä½œç‚ºèµ·å§‹æ²»ç™‚

## å®‰å…¨æ€§è€ƒé‡

### å·²çŸ¥é¢¨éšª
- **å‘¨é‚Šæ°´è…«**ï¼šæœ€å¸¸è¦‹å‰¯ä½œç”¨ï¼Œèˆ‡åŠ‘é‡ç›¸é—œ
- **é ­ç—›**ï¼šè¡€ç®¡æ“´å¼µç›¸é—œ
- **æ½®ç´…**ï¼šç´„ 10% æ‚£è€…
- **å¿ƒæ‚¸**ï¼šåå°„æ€§å¿ƒè·³åŠ é€Ÿ
- **ç‰™é½¦å¢ç”Ÿ**ï¼šé•·æœŸä½¿ç”¨å¯èƒ½ç™¼ç”Ÿ

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | æ©Ÿè½‰ | è‡¨åºŠæ„ç¾© |
|-------------|------|---------|
| CYP3A4 æŠ‘åˆ¶åŠ‘ | ä»£è¬æ¸›æ…¢ | è¡€å£“éåº¦é™ä½ |
| è‘¡è„æŸšæ± | CYP3A4 æŠ‘åˆ¶ | é¿å…ä½µç”¨ |
| Beta-blockers | å”åŒé™å£“ | å¯èƒ½éœ€è¦æ¸›é‡ |
| Digoxin | è¡€ä¸­æ¿ƒåº¦å‡é«˜ | ç›£æ¸¬ digoxin æ¿ƒåº¦ |

### ç‰¹æ®Šæ—ç¾¤
- **å­•å©¦**ï¼šC ç´šï¼Œä¸å»ºè­°ä½¿ç”¨
- **å“ºä¹³**ï¼šåˆ†æ³Œè‡³ä¹³æ±ï¼Œä¸å»ºè­°ä½¿ç”¨
- **è‚åŠŸèƒ½ä¸å…¨**ï¼šéœ€æ¸›é‡
- **è€å¹´äºº**ï¼šå¯èƒ½éœ€è¼ƒä½èµ·å§‹åŠ‘é‡

### è‚ºé«˜å£“ç‰¹æ®Šè€ƒé‡
å¦‚ç”¨æ–¼è‚ºé«˜å£“ï¼Œéœ€æ³¨æ„ï¼š
- åƒ…å°è¡€ç®¡åæ‡‰æ€§é™½æ€§çš„æ‚£è€…æœ‰æ•ˆ
- éœ€åœ¨å°ˆæ¥­ä¸­å¿ƒé€²è¡Œæ€¥æ€§è¡€ç®¡åæ‡‰æ€§è©¦é©—
- å¯èƒ½å°è‡´å…¨èº«æ€§ä½è¡€å£“è€Œæƒ¡åŒ–å³å¿ƒåŠŸèƒ½




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é…’ç²¾** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚éœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚

**è‘¡è„æŸšæ±** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šé¿å…å¤§é‡æ”å–ã€‚éœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘ç™‚æ•ˆ
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**å¿ƒè‡Ÿè¡°ç«­** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Shock, Cardiogenic** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚

**Coronary Artery Disease** ğŸŸ¢ Minor
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°
æ­¤é æ¸¬**ä¸å»ºè­°ç›´æ¥è‡¨åºŠæ‡‰ç”¨**ï¼ŒåŸå› å¦‚ä¸‹ï¼š
1. ç¼ºä¹å°ˆé–€çš„è‡¨åºŠè©¦é©—è­‰æ“š
2. ç¾æœ‰æ›´æœ‰æ•ˆçš„è‚ºé«˜å£“å°ˆç”¨è—¥ç‰©
3. Felodipine å°è‚ºè¡€ç®¡çš„é¸æ“‡æ€§ä¸å¦‚å…¶ä»–è—¥ç‰©
4. æƒ¡æ€§é«˜è¡€å£“é€šå¸¸éœ€è¦æ›´ç©æ¥µçš„ä»‹å…¥æ²»ç™‚

### å»ºè­°è¡Œå‹•
- [ ] å°æ–¼æƒ¡æ€§é«˜è¡€å£“ï¼Œå¯ä½¿ç”¨å…¶ä»–æ›´å¿«é€Ÿä½œç”¨çš„é™å£“è—¥
- [ ] è‚ºé«˜å£“æ‡‰ç”±å°ˆç§‘é†«å¸«ä½¿ç”¨æ ¸å‡†çš„å°ˆé–€è—¥ç‰©æ²»ç™‚
- [ ] ä¸å»ºè­°å°‡ felodipine ä½œç‚ºé€™äº›é©æ‡‰ç—‡çš„ä¸€ç·šé¸æ“‡

### ç‰¹æ®Šæƒ…æ³è€ƒé‡
åœ¨ç„¡æ³•å–å¾—å°ˆé–€è‚ºé«˜å£“è—¥ç‰©çš„ç·Šæ€¥æƒ…æ³ä¸‹ï¼Œéˆ£é›¢å­é€šé“é˜»æ–·åŠ‘å¯èƒ½æ˜¯ä¸€å€‹å‚™é¸ï¼Œä½†éœ€è¦å¯†åˆ‡ç›£æ¸¬ã€‚

### é¢¨éšªç­‰ç´š
**é«˜é¢¨éšª** - ä¸å»ºè­°è¶…é©æ‡‰ç—‡ä½¿ç”¨æ–¼è‚ºé«˜å£“ï¼›æƒ¡æ€§é«˜è¡€å£“éœ€è¦æ›´ç©æ¥µçš„æ²»ç™‚ç­–ç•¥

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN é æ¸¬ã€ClinicalTrials.govã€PubMedã€TFDA*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Lidocaine]({{ "/drugs/lidocaine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Fenoterol]({{ "/drugs/fenoterol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tenofovir Alafenamide]({{ "/drugs/tenofovir_alafenamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alirocumab]({{ "/drugs/alirocumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Felodipineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/felodipine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_felodipine,
  title = {Felodipineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/felodipine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
